Department of Family Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Arch Dis Child. 2014 Sep;99(9):807-11. doi: 10.1136/archdischild-2013-305275. Epub 2014 Apr 19.
To determine whether children with calcium-deficiency rickets have a better response to treatment with vitamin D and calcium than with calcium alone.
Randomised controlled trial.
Jos University Teaching Hospital, Jos, Nigeria.
Nigerian children with active rickets treated with calcium carbonate as limestone (approximately 938 mg elemental calcium twice daily) were, in addition, randomised to receive either oral vitamin D2 50,000 IU (Ca+D, n=44) or placebo (Ca, n=28) monthly for 24 weeks.
Achievement of a 10-point radiographic severity score ≤1.5 and serum alkaline phosphatase ≤350 U/L.
The median (range) age of enrolled children was 46 (15-102) months, and baseline characteristics were similar in the two groups. Mean (±SD) 25-hydroxyvitamin D (25(OH)D) was 30.2±13.2 nmol/L at baseline, and 29 (43%) had values <30 nmol/L. Baseline alkaline phosphatase and radiographic scores were unrelated to vitamin D status. Of the 68 children (94% of original cohort) who completed 24 weeks of treatment, 29 (67%) in the Ca+D group and 11 (44%) in the Ca group achieved the primary outcome (p=0.06). Baseline 25(OH)D did not alter treatment group effects (p=0.99 for interaction). At the end of 24 weeks, 25(OH)D values were 55.4±17.0 nmol/L and 37.9±20.0 nmol/L in the Ca+D and Ca groups, respectively, (p<0.001). In the Ca+D and Ca groups, the final 25(OH)D concentration was greater in those who achieved the primary outcome (56.4±17.2 nmol/L) than in those who did not (37.7±18.5 nmol/L, p<0.001).
In children with calcium-deficiency rickets, there is a trend for vitamin D to improve the response to treatment with calcium carbonate as limestone, independent of baseline 25(OH)D concentrations.
ClinicalTrials.gov NCT00949832.
确定儿童佝偻病是否对维生素 D 和钙的联合治疗比单纯补钙有更好的反应。
随机对照试验。
尼日利亚乔斯大学教学医院。
接受碳酸钙(约 938mg 元素钙,每日两次)治疗的尼日利亚活动性佝偻病儿童,另外随机接受口服维生素 D2 50,000IU(Ca+D,n=44)或安慰剂(Ca,n=28)每月治疗 24 周。
达到 10 分放射性严重程度评分≤1.5 和血清碱性磷酸酶≤350U/L。
入组儿童的中位(范围)年龄为 46(15-102)个月,两组基线特征相似。治疗前 25-羟维生素 D(25(OH)D)的平均值(±SD)为 30.2±13.2nmol/L,29%(43%)的 25(OH)D 值<30nmol/L。基线碱性磷酸酶和放射性评分与维生素 D 状态无关。68 名(原始队列的 94%)完成 24 周治疗的儿童中,Ca+D 组 29 名(67%)和 Ca 组 11 名(44%)达到主要终点(p=0.06)。基线 25(OH)D 并未改变治疗组的效果(p=0.99 交互作用)。24 周结束时,Ca+D 组和 Ca 组的 25(OH)D 值分别为 55.4±17.0nmol/L 和 37.9±20.0nmol/L(p<0.001)。在 Ca+D 和 Ca 组中,达到主要终点的患者的最终 25(OH)D 浓度(56.4±17.2nmol/L)高于未达到主要终点的患者(37.7±18.5nmol/L,p<0.001)。
在患有佝偻病的儿童中,维生素 D 可改善碳酸钙(石灰岩)治疗的反应,这与基线 25(OH)D 浓度无关。
ClinicalTrials.gov NCT00949832。